Challenges and Solutions in Biologic Therapies Product Manufacturing

In the intricate realm of injectable formulation development, crafting effective solutions for biologic therapies demands meticulous attention to detail and innovative approaches. Unlike conventional small molecule products, biologics necessitate specialized small batch aseptic filler techniques (Singota Solution's specialty) tailored to their unique properties and parenteral administration requirements. Formulation scientists and…

Advancing Aseptic Filling: Evaluating The Revolutionary SA25 Workcell

In the ever-evolving landscape of injectable formulation development, aseptic filling, and aseptic manufacturing solutions, the SA25 Workcell, a groundbreaking innovation crafted by Vanrx (now Cytiva) that Singota Solution's (CDMO in Bloomington, Indiana) pioneered in North America, emerges as a beacon of progress. This state-of-the-art technology represents a significant leap in…

Captisol®: What gives EuropeanPharmacopeia?!

Analytical Method Challenges for EP Monograph, Captisol ® At the 2023 American Drug Delivery and Formulation Summit, Ryan Memmer from Singota Solutions (leading CDMO in Bloomington, Indiana), captivated the audience with his insightful presentation on "Analytical Method Challenges for EP Monograph," titled "Captisol®: What gives European Pharmacopeia?!" Memmer's expertise in…

Analysis Paralysis: Navigating Early-Phase Analytical Validation

Significant confusion persists across the pharmaceutical/biopharmaceutical industry relevant to early-phase analytical development and analytical validation. While several guidance documents serve as a de facto standard, distinguishing method validation requirements from suggestions, when and how to apply those guidelines often is not a straightforward task.It is critical to establish a product/project’s…

Posts pagination